ENDRA Life Sciences (NDRA) Non Operating Interest Expenses (2016 - 2024)

ENDRA Life Sciences (NDRA) has reported Non Operating Interest Expenses for 7 consecutive years, with $4841.0 the latest figure, recorded in Q1 2024.

• On a quarterly basis, Non Operating Interest Expenses rose 41.63% year-over-year to $4841.0 in Q1 2024; TTM through Mar 2024 was $13229.0, a 58.78% decrease from a year earlier, with the FY2017 full-year figure at $750904.0, down 23.66% from the prior year.
• Non Operating Interest Expenses was $4841.0 for Q1 2024 at ENDRA Life Sciences, up from $3418.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $4841.0 in Q1 2024 and troughed at $2037.0 in Q1 2021.
• A 4-year average of $3307.2 and a median of $3175.5 in 2022 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses jumped 43.99% in 2022 and rose 16.54% in 2023, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $2037.0 in 2021, then jumped by 43.99% to $2933.0 in 2022, then increased by 16.54% to $3418.0 in 2023, then jumped by 41.63% to $4841.0 in 2024.
• The last three Non Operating Interest Expenses figures came in at $4841.0 (Q1 2024), $3418.0 (Q1 2023), and $2933.0 (Q1 2022), per Business Quant data.